Covid-19 Early Treatment Fund Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2020
NCT04668950
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Covid-19 Early Treatment Fund

Active Ingredients

Drugs in Phase 3 Trials (2)

cyproheptadine (periactin) (1 trial)

fluvoxamine (luvox) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2